Literature DB >> 29114005

Residual Kidney Function and Peritoneal Dialysis-Associated Peritonitis Treatment Outcomes.

Rachel Whitty1,2, Joanne M Bargman3, Alex Kiss4, Linda Dresser2,5, Philip Lui2,6.   

Abstract

BACKGROUND AND OBJECTIVES: Residual kidney function contributes to the clearance of antibiotics excreted by the kidneys, lowering the antibiotic concentration, which may adversely affect the treatment of peritoneal dialysis-associated peritonitis. The objective of our study was to examine the relationship between residual kidneyfunction and peritonitis treatment outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our study included 181 participants who experienced 339 episodes of Gram-positive, Gram-negative, and culture-negative peritoneal dialysis-associated peritonitis at a single centerfrom 2003 to 2010. Episodes were categorized according to participants' urinary creatinine clearance (0, >0-5, and >5 ml/min). The data were analyzed using generalized estimating equation models to determine the covariate-adjusted association between urinary creatinine clearance and treatment failure (defined as relapse or recurrent peritonitis episodes, peritoneal catheter removal, or death from any cause during peritonitis treatment).
RESULTS: Among episodes of peritonitis due to Gram-positive organisms or culture-negative infections, those experienced by participants with urinary creatinine clearance >5 ml/min had significantly higher odds of treatment failure than episodes experienced by anuric participants (27 of 80 versus 20 of 119 episodes resulting in treatment failure for creatinine clearance >5 versus 0 ml/min; odds ratio, 6.80; 95% confidence interval, 2.37 to 19.6). Episodes experienced by participants with creatinine clearance >0-5 ml/min also had significantly higher odds of treatment failure than episodes experienced by anuric participants (14 of 64 episodes resulting in treatment failure for creatinine clearance >0-5 ml/min; odds ratio, 2.87; 95% confidence interval, 1.12 to 7.35). The odds of relapse and recurrent peritonitis among participants with creatinine clearance >5 ml/min was also significantly higher compared with in anuric participants (17 of 80 versus 12 of 119 episodes resulting in relapse and recurrence for creatinine clearance >5 versus 0 ml/min; odds ratio, 6.76; 95% confidence interval, 1.90 to 23.8). Among participants with Gram-negative peritonitis, creatinine clearance was significantly associated with neither treatment failure nor relapse and recurrent peritonitis.
CONCLUSIONS: Residual kidney function as measured by greater urinary creatinine clearance was associated with treatment failure among participants with Gram-positive and culture-negative peritonitis.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  Anti-Bacterial Agents; Recurrence; Treatment Failure; Treatment Outcome; antibiotic clearance; continuous ambulatory peritoneal dialysis; continuous cyclic peritoneal dialysis; creatinine; peritoneal dialysis; peritonitis; residual kidney function

Mesh:

Substances:

Year:  2017        PMID: 29114005      PMCID: PMC5718262          DOI: 10.2215/CJN.00630117

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  15 in total

1.  Correlation of intraperitoneal antibiotic pharmacokinetics and peritoneal membrane transport characteristics.

Authors:  R J Elwell; G R Bailie; H J Manley
Journal:  Perit Dial Int       Date:  2000 Nov-Dec       Impact factor: 1.756

Review 2.  Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes.

Authors:  Yeoungjee Cho; David W Johnson
Journal:  Am J Kidney Dis       Date:  2014-04-18       Impact factor: 8.860

3.  Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients.

Authors:  T Tosukhowong; S Eiam-Ong; K Thamutok; S Wittayalertpanya; D P Na Ayudhya
Journal:  Perit Dial Int       Date:  2001 Nov-Dec       Impact factor: 1.756

Review 4.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

5.  Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis.

Authors:  Harold J Manley; George R Bailie; Reginald Frye; Lorraine D Hess; M Donald McGoldrick
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

6.  The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis.

Authors:  Sarah Stevenson; Wen Tang; Yeoungjee Cho; David W Mudge; Carmel M Hawley; Sunil V Badve; David W Johnson
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

7.  Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients.

Authors:  J G Mulhern; G L Braden; M H O'Shea; R L Madden; G S Lipkowitz; M J Germain
Journal:  Am J Kidney Dis       Date:  1995-04       Impact factor: 8.860

8.  Single UK centre experience on the treatment of PD peritonitis--antibiotic levels and outcomes.

Authors:  Mark Blunden; Deborah Zeitlin; Neil Ashman; Stanley L-S Fan
Journal:  Nephrol Dial Transplant       Date:  2007-03-17       Impact factor: 5.992

9.  Pharmacokinetics of intermittent intraperitoneal ceftazidime.

Authors:  D W Grabe; G R Bailie; G Eisele; R F Frye
Journal:  Am J Kidney Dis       Date:  1999-01       Impact factor: 8.860

Review 10.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

View more
  7 in total

Review 1.  Peritoneal Dialysis-Associated Peritonitis.

Authors:  Cheuk-Chun Szeto; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-08       Impact factor: 8.237

2.  Effective Treatment of PD Peritonitis.

Authors:  Beth Piraino
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

Review 3.  Sodium toxicity in peritoneal dialysis: mechanisms and "solutions".

Authors:  Silvio Borrelli; Luca De Nicola; Roberto Minutolo; Alessandra Perna; Michele Provenzano; Gennaro Argentino; Gianfranca Cabiddu; Roberto Russo; Vincenzo La Milia; Toni De Stefano; Giuseppe Conte; Carlo Garofalo
Journal:  J Nephrol       Date:  2019-11-16       Impact factor: 3.902

4.  Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.

Authors:  E T Van Matre; I Teitelbaum; T H Kiser
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

5.  Rhizobium radiobacter-Induced Peritonitis: A Case Report and Literature Analysis.

Authors:  Sasmit Roy; Debargha Basuli; Ebad U Rahman; Sreedhar Adapa; Sohil N Reddy
Journal:  J Med Cases       Date:  2022-09-28

6.  Variability in Culture-Negative Peritonitis Rates in Pediatric Peritoneal Dialysis Programs in the United States.

Authors:  T Keefe Davis; Kristina A Bryant; Jonathan Rodean; Troy Richardson; Rangaraj Selvarangan; Xuan Qin; Alicia Neu; Bradley A Warady
Journal:  Clin J Am Soc Nephrol       Date:  2021-01-18       Impact factor: 8.237

7.  Red blood cell distribution width and peritoneal dialysis-associated peritonitis prognosis.

Authors:  Peng He; Jin-Ping Hu; Huan Li; Xiu-Juan Tian; Li-Jie He; Shi-Ren Sun; Chen Huang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.